Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$56.6 million.

  • Compass Therapeutics' Income towards Parent Company fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 41.55%. This contributed to the annual value of -$56.6 million for FY2024, which is 33.25% down from last year.
  • Latest data reveals that Compass Therapeutics reported Income towards Parent Company of -$56.6 million as of FY2024, which was down 33.25% from -$42.5 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Income towards Parent Company ranged from a high of -$37,483 in FY2020 and a low of -$82.2 million during FY2021.
  • Over the past 3 years, Compass Therapeutics' median Income towards Parent Company value was -$42.5 million (recorded in 2023), while the average stood at -$46.1 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 178.58% in 2021, then spiked by 52.27% in 2022.
  • Over the past 5 years, Compass Therapeutics' Income towards Parent Company (Yearly) stood at -$37,483 in 2020, then grew by 15.09% to -$29.5 million in 2020, then tumbled by 178.58% to -$82.2 million in 2021, then surged by 52.27% to -$39.2 million in 2022, then decreased by 8.33% to -$42.5 million in 2023, then plummeted by 33.25% to -$56.6 million in 2024.